UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number 001-42981
DAVION HEALTHCARE PLC
(Translation of registrant's name into English)
Unit A, West Cork Business & Technology
Park
Clonakilty, County Cork, P85 FV48 Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Agreement to Acquire Healthcare Stat
Homecare Inc.
On
October 29, 2026, Davion Healthcare Plc (the “Company”
or “Davion”)
issued a press release announcing that it had entered into an agreement dated October 27, 2026 to acquire Healthcare Stat Homecare Inc.
(“HSH”),
a Pennsylvania-incorporated provider of home healthcare services based in Philadelphia.
The total consideration for the proposed
acquisition is $13.5 million, comprising $8 million in cash and $5.5 million in Company shares to be issued at an agreed value of $13
per share. Completion is expected on or before December 31, 2026, subject to the terms of the acquisition agreement.
HSH is an established, revenue-generating
and profitable healthcare services business. For the year ended December 31, 2025, HSH reported gross receipts of approximately $11.6
million and ordinary business income of approximately $1.9 million, in each case on an unaudited basis. Following completion, the acquisition
is expected to provide the Company with an established operating business and an additional source of revenue and earnings.
HSH
provides skilled nursing, home health aide and rehabilitation services to patients in Philadelphia and surrounding areas. Its clinical
programmes include wound care, lymphedema management, dementia and diabetes care, telehealth and rehabilitation. HSH serves patients of
all ages, supporting the delivery of care in patients’ homes, and
its workforce includes registered nurses, licensed practical nurses, home health aides, physical and occupational therapists and social
workers.
The
proposed acquisition represents the first in a planned programme of acquisitions of established, revenue-generating and profitable healthcare
businesses over the coming year. This strategy is intended to complement the Company’s
existing portfolio of proprietary healthcare technologies, broaden its commercial operations and build a more diversified healthcare group.
The
acquisition would extend the Company’s activities beyond the development
and commercialisation of healthcare products into the delivery of care in patients’ homes.
It could also provide opportunities to evaluate the use of the Company’s
non-invasive monitoring technologies in home healthcare, including wound monitoring and preventative care. Any integration or deployment
plans will be developed following completion.
EXHIBIT INDEX
Exhibit No. - Description
99.1
Press release dated October 29, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DAVION HEALTHCARE PLC
By: /s/ Glenn Williams
Name: Glenn Williams
Title: Chief Executive Officer
Date: October 29, 2026
Exhibit 99.1
For release 29 October 2026
DAVION HEALTHCARE PLC AGREES $13.5 MILLION
ACQUISITION OF PROFITABLE US HOME HEALTHCARE BUSINESS
First in a planned programme
of acquisitions to expand Davion’s revenues, earnings and healthcare operations
Davion Healthcare Plc (NASDAQ: DAVI)
(“Davion” or the “Group”), a developer of non-invasive health monitoring technologies, announces that it has
entered into an agreement dated 27 October 2026 to acquire Healthcare Stat Homecare Inc. (“HSH”), a
Pennsylvania-incorporated provider of home healthcare services based in Philadelphia.
The total consideration is $13.5 million, comprising
$8 million in cash and $5.5 million in Davion shares issued at an agreed value of $13 per share. Completion is expected on or before 31
December 2026, subject to the terms of the acquisition agreement.
HSH is an established, revenue-generating and profitable
healthcare services business. For the year ended 31 December 2025, HSH reported gross receipts of approximately $11.6 million and ordinary
business income of approximately $1.9 million (unaudited). The acquisition is expected to provide Davion with an established operating
business and an additional source of revenue and earnings following completion.
The proposed acquisition represents the first in a
planned programme of acquisitions of established, revenue-generating and profitable healthcare businesses over the coming year. This strategy
is intended to complement Davion’s existing portfolio of proprietary healthcare technologies, broaden its commercial operations
and build a more diversified healthcare group.
HSH provides skilled nursing, home health aide and rehabilitation
services to patients in Philadelphia and surrounding areas. Its clinical programmes include wound care, lymphedema management, dementia
and diabetes care, telehealth and rehabilitation. Its workforce includes registered nurses, licensed practical nurses, home health aides,
physical and occupational therapists and social workers.
HSH provides care to patients of all ages, from
children to the elderly, helping individuals remain in their own homes rather than requiring residential or institutional care.
According to its website, HSH holds JCAHO accreditation and Medicare and Medicaid certifications, is fully insured and bonded, and
accepts major insurance plans.
The acquisition would also extend Davion’s
activities beyond the development and commercialisation of healthcare products into the delivery of care in patients’ homes.
It could provide opportunities to evaluate the use of Davion’s non-invasive monitoring technologies in home healthcare,
including wound monitoring and preventative care. Any integration or deployment plans will be developed following completion.
Glenn Williams, Chief Executive Officer of Davion,
commented:
“HSH is an established and profitable
business that will bring meaningful revenues and earnings to Davion, while giving us a direct presence in home healthcare and
opportunities to introduce our monitoring and diagnostic technologies closer to patients. Importantly, this is the first in a
planned programme of acquisitions of revenue-generating, profitable healthcare businesses over the coming year, as we look to build
a broader and more diversified Group combining our proprietary technologies with established operating businesses. We look forward
to working with HSH’s management to support its existing operations and explore opportunities to integrate our technologies
into the delivery of care at home.”
Manilal Mathai, Co-owner and Chief Executive Officer
of HSH, added:
“We share Davion’s
commitment to improving care for patients outside hospital settings. Joining forces would give us an opportunity to combine HSH’s
home healthcare experience with Davion’s technology-led approach, while continuing to focus on the quality and continuity of care
we provide to patients and families.”
-ends-
Media Enquiries
Rosewood Communications
+44 (0) 20 7653 8702
davion@rosewoodpr.co.uk
Investor Relations Inquiries
Mark Komonoski
Partner
Integrous Communications
Toll Free: 877-255-8483
Mobile: 403-470-8384
About Davion Healthcare Plc
Davion Healthcare Plc is a next-generation digital healthcare
company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies
outside traditional clinical environments.
The Company’s flagship product, BreastCheck, is
an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast
temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin
anomalies, wound monitoring, blood pressure and other areas of preventive healthcare.
Davion’s growth strategy combines the development
and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group’s product portfolio
and commercial, manufacturing and distribution capabilities.
Further information is available at www.davionhealthcare.com.
Forward-Looking Statements
This announcement contains forward-looking statements within
the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, those identified by words such as “believes,” “will,” “expects,”
“anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects”
and similar expressions.
The statements in this release are based upon the current
beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may
differ from those set forth in these forward-looking statements.
Numerous factors could cause or contribute to such
differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption
and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive
products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in
the future, changes in government policy and/or regulation, potential litigation by or against the Company, any governmental review
of its products or practices, and other risks discussed from time to time in the Company’s filings with the Securities and
Exchange Commission.
The Company undertakes no obligation to update any forward-looking
statements, or any information contained in this press release or in other public disclosures, at any time, except as required by applicable
law.
The investing public is reminded that only announcements
or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.
